The study is expected to evaluate the safety of Iomab-ACT in sickle cell disease patients undergoing allogeneic bone marrow transplantation.
FDA Approves Actinium Pharmaceuticals’ Investigational New Drug Application for Iomab-ACT for Patients with Sickle Cell Disease
Leave a comment
